Helen S. Kim, M.B.A., joined our board of directors in August 2018, bringing with her over 27 years of leadership experience in biotechnology. Ms. Kim currently serves as managing director of Vida Ventures, a position she has held since April 2019. From March 2018 to March 2019, Ms. Kim served as a partner at The Column Group. From June 2014 to January 2018, Ms. Kim served as executive vice president of Business Development at Kite Pharma, Inc. where she led all business and corporate development initiatives, including the successful buyout of Kite Pharma to Gilead in 2017. From August 2009 to November 2014, she served in various roles as strategic advisor and chief business officer at NGM Biopharmaceuticals, Inc. Prior to NGM, she was the chief executive officer and president of Kosan Biosciences where she restructured and repositioned the company prior to successfully selling the company to Bristol-Myers Squibb in 2008. She holds a B.S. in Chemical Engineering from Northwestern University and a M.B.A. from the University of Chicago. Ms. Kim also currently serves on the Board of Directors for Assembly Biosciences, A2 Biotherapeutics, Neogene and Exicure, Inc.